UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL)

Hematological oncology, 2023-06, Vol.41 (S2), p.587-589

2023

Volltextzugriff (PDF)

P1154: STUDY ZILO‐301: A PHASE 3, RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED, MULTICENTER STUDY OF ZILOVERTAMAB PLUS IBRUTINIB VS IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA

HemaSphere, 2022-06, Vol.6 (Suppl), p.1041-1042

2022

Volltextzugriff (PDF)

PP-149 GLUCOSE LEVEL IN PATIENTS WITHIN RECENT ACUTE CORONARY SYNDROME WHO UNDERGO CORONARY ANGIOGRAPHY

International journal of cardiology, 2013-03, Vol.163 (3), p.S139-S139

2013

Volltextzugriff (PDF)

PD-011Safety and efficacy analysis of imalumab, an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody, alone or in combination with 5-fluorouracil/leucovorin (5-FU/LV) or panitumumab, in patients with metastatic colorectal cancer (mCRC)

Annals of oncology, 2016-06, Vol.27 (suppl_2), p.ii105-ii105

2016

Volltextzugriff (PDF)

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023

Hematological oncology, 2023-06, Vol.41 Suppl 2, p.587

2023

Volltextzugriff (PDF)

A fully human anti-oxMIF antibody penetrates colorectal cancer metastases and accumulates in cancer tissue

Annals of oncology, 2015-03, Vol.26, p.ii16

2015

Volltextzugriff (PDF)

P1.10A fully human anti-oxMIF antibody penetrates colorectal cancer metastases and accumulates in cancer tissue

Annals of oncology, 2015-03, Vol.26 (suppl_2), p.ii18-ii18

2015

Volltextzugriff (PDF)

395 POSTER Phase I study of XL844, a novel Chk1 and Chk2 kinase inhibitor, in combination with gemcitabine in patients with advanced malignancies

European journal of cancer supplements, 2008, Vol.6 (12), p.124-124

2008

Volltextzugriff (PDF)

212 POSTER A phase II study of the KIT inhibitor XL820 in patients with advanced gastrointestinal stromal tumors (GIST) resistant to or intolerant of imatinib and/or sunitinib

European journal of cancer supplements, 2008, Vol.6 (12), p.67-67

2008

Volltextzugriff (PDF)

383 POSTER A phase 1 study of XL281, a potent and selective inhibitor of RAF kinases, administered orally to patients (pts) with advanced solid tumors

European journal of cancer supplements, 2008, Vol.6 (12), p.120-120

2008

Volltextzugriff (PDF)

Anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody imalumab (BAX69) in advanced solid tumors: Final results of first-in-human phase 1 study

Annals of oncology, 2016-10, Vol.27, p.vi116-vi116

2016

Volltextzugriff (PDF)

Final results from phase II study of volociximab, an α5β1 anti-integrin antibody, in refractory or relapsed metastatic clear cell renal cell carcinoma (mCCRCC)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.5094-5094

2007

Volltextzugriff (PDF)

Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): First results from ENEST g3

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.10017-10017

2010

Volltextzugriff (PDF)

Final results from cohort 1 of a phase II study of volociximab, an anti-α5β1 integrin antibody, in combination with gemcitabine (GEM) in patients (pts) with metastatic pancreatic cancer (MPC)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.4549-4549

2007

Volltextzugriff (PDF)

Phase II study of volociximab (M200), an α5β1 anti-integrin antibody in refractory metastatic clear cell renal cell cancer (RCC)

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.4535-4535

2006

Volltextzugriff (PDF)

Phase II study of volociximab (M200), an α5β1 anti-integrin antibody in metastatic adenocarcinoma of the pancreas (MPC)

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.4111-4111

2006

Volltextzugriff (PDF)

Phase II study of volociximab (M200), an α5β1 anti-integrin antibody in metastatic melanoma

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.8011-8011

2006

Volltextzugriff (PDF)

Vomiting after ophthalmic surgery. Effects of intra-operative antiemetics and postoperative oral fluid restriction

Anaesthesia, 1987-03, Vol.42 (3), p.270-276

1987

Volltextzugriff (PDF)

65 POSTER Safety of Volociximab as a monotherapy and in combination with chemotherapy the result of three phase II studies

European journal of cancer supplements, 2006-11, Vol.4 (12), p.24-24

2006

Volltextzugriff (PDF)

The Effect of the Characteristic Distance of the Correlation Function on the Optimal Design of Geodetic Networks

Acta geodaetica et geophysica Hungarica, 1998-06, Vol.33 (2-4), p.215-234

Yazji, S.

1998

Volltextzugriff (PDF)

Convulsive reaction following enflurane anaesthesia

Anaesthesia, 1984-12, Vol.39 (12), p.1249-1249

1984

Volltextzugriff (PDF)

A motion-estimation architecture based on band-matching

Conference Record of the Thirty-First Asilomar Conference on Signals, Systems and Computers (Cat. No.97CB36136), 1997, Vol.1, p.421-425 vol.1

1997

Volltextzugriff (PDF)

A band-matching approach for motion estimation

Proceedings of 40th Midwest Symposium on Circuits and Systems. Dedicated to the Memory of Professor Mac Van Valkenburg, 1997, Vol.2, p.909-912 vol.2

1997

Volltextzugriff (PDF)

Vomiting after ophthalmic surgery

Anaesthesia, 1987-03, Vol.42 (3), p.270-276

1987

Volltextzugriff (PDF)

1 – 25 von 93

Suche als RSS-Feed

Aktive Filter

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(67)
Mit Volltextzugriff
(69)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(6)
Male
(5)
Patients
(5)
Economics
(4)
Surgery
(4)
Adult
(3)
Criterion Matrix
(3)
Female
(3)
Hematology, Oncology And Palliative Medicine
(3)
Middle Aged
(3)
Mortality
(3)
Regulation
(3)
S.O.D
(3)
Women
(3)
Aged
(2)
Aged, 80 And Over
(2)
Anemia
(2)
Asthma
(2)
Biological And Medical Sciences
(2)
Business & Economics
(2)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL)

P1154: STUDY ZILO‐301: A PHASE 3, RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED, MULTICENTER STUDY OF ZILOVERTAMAB PLUS IBRUTINIB VS IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA

PP-149 GLUCOSE LEVEL IN PATIENTS WITHIN RECENT ACUTE CORONARY SYNDROME WHO UNDERGO CORONARY ANGIOGRAPHY

PD-011Safety and efficacy analysis of imalumab, an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody, alone or in combination with 5-fluorouracil/leucovorin (5-FU/LV) or panitumumab, in patients with metastatic colorectal cancer (mCRC)

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023

A fully human anti-oxMIF antibody penetrates colorectal cancer metastases and accumulates in cancer tissue

P1.10A fully human anti-oxMIF antibody penetrates colorectal cancer metastases and accumulates in cancer tissue

395 POSTER Phase I study of XL844, a novel Chk1 and Chk2 kinase inhibitor, in combination with gemcitabine in patients with advanced malignancies

212 POSTER A phase II study of the KIT inhibitor XL820 in patients with advanced gastrointestinal stromal tumors (GIST) resistant to or intolerant of imatinib and/or sunitinib

383 POSTER A phase 1 study of XL281, a potent and selective inhibitor of RAF kinases, administered orally to patients (pts) with advanced solid tumors

Anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody imalumab (BAX69) in advanced solid tumors: Final results of first-in-human phase 1 study

PD-011 Safety and efficacy analysis of imalumab, an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody, alone or in combination with 5-fluorouracil/leucovorin (5-FU/LV) or panitumumab, in patients with metastatic colorectal cancer (mCRC)

Final results from phase II study of volociximab, an α5β1 anti-integrin antibody, in refractory or relapsed metastatic clear cell renal cell carcinoma (mCCRCC)

Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): First results from ENEST g3

Final results from cohort 1 of a phase II study of volociximab, an anti-α5β1 integrin antibody, in combination with gemcitabine (GEM) in patients (pts) with metastatic pancreatic cancer (MPC)

Phase II study of volociximab (M200), an α5β1 anti-integrin antibody in refractory metastatic clear cell renal cell cancer (RCC)

Phase II study of volociximab (M200), an α5β1 anti-integrin antibody in metastatic adenocarcinoma of the pancreas (MPC)

Phase II study of volociximab (M200), an α5β1 anti-integrin antibody in metastatic melanoma

Vomiting after ophthalmic surgery. Effects of intra-operative antiemetics and postoperative oral fluid restriction

65 POSTER Safety of Volociximab as a monotherapy and in combination with chemotherapy the result of three phase II studies

The Effect of the Characteristic Distance of the Correlation Function on the Optimal Design of Geodetic Networks

Convulsive reaction following enflurane anaesthesia

A motion-estimation architecture based on band-matching

A band-matching approach for motion estimation

Vomiting after ophthalmic surgery

Aktive Filter

Suchergebnisse filtern